NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by:
Deborah M. Stephens
Search for other papers by Deborah M. Stephens in
Current site
Google Scholar
PubMed
Close
 DO
Restricted access

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized by the accumulation of abnormal lymphocytes in the blood, bone marrow, and lymphoid tissues, leading to a weakened immune system and an increased risk of infections for patients. The NCCN Guidelines for CLL/SLL underscore the need for a comprehensive evaluation of multiple factors to determine the most appropriate treatment approach for each patient. For frontline therapy, the selection process should consider the patient’s IGHV status, del(17p)/TP53 mutation status, age, and comorbidities. In choosing subsequent therapy, prior therapy, comorbidities, and resistance mutations should be considered. With no clear evidence of a functional cure, it is important to enroll patients in clinical trials when available.

Disclosures: Dr. Stephens has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, BeiGene, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, and Genentech, Inc.

Correspondence: Deborah M. Stephens, DO, Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Room 5509, Salt Lake City, UT 84112. Email: deborah.stephens@hci.utah.edu
  • Collapse
  • Expand
  • 1.

    Wierda WG, Brown J, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2023. Accessed April 11, 2023. Available at: https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Eichhorst B, Niemann C, Kater A, et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. Presented at the 27th Congress of the European Hematology Association 2022; June 9–12, 2022; Vienna, Austria. Abstract LB2365.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1:EVIDoa2200006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378:11071120.

  • 5.

    Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv 2022;6:45534557.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:34413452.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319332.

  • 8.

    Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 2021;397:892901.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 6549 5929 540
PDF Downloads 6125 5600 508
EPUB Downloads 0 0 0